Home | About Us | Contact Us | Site Map | Locations
University of Washington Department of Urology Seal University of Washington | School of Medicine
Department of Urology
University of Washington | School of Medicine
Department of Urology

Eva Corey, PhD

Research Associate Professor
Department of Urology
School of Medicine
University of Washington

Education & Training

Dr. Corey received her RNDr. (M.S.) in 1989 from Charles University, Prague, Czechoslovakia, and her PhD in Organic Chemistry with specialization in Peptide Chemistry from the Czechoslovak Academy of Sciences, Prague, Czechoslovakia. She did postdoctoral studies in London at the University of London, School of Pharmacy, on synthesis of fragments of HIV p24; at the University of Colorado with Professor John M. Stewart in Denver, CO, on synthesis, purification, and characterization of an artificial enzyme; and at the University of Washington, Seattle, WA, where she concentrated on various aspects on prostate cancer.

Research Interests

>>Genitourinary Cancer Research Laboratory

Dr. Corey's major research objective is to investigate the molecular events associated with the progression of prostate cancer and with prostate cancer metastasis to bone, with emphasis on roles osteoprotegerin, RANKL and bone morphogenetic proteins, interactions between tumor and bone cells and signal transduction pathways involved in establishment and development of osteoblastic bone metastasis. Dr. Corey through collaboration with Dr. Vessella is also involved in the program of establishment and generation of novel prostate cancer xenografts of prostate cancer and tissues acquisition.

Research Funding

  • Mechanisms and Markers of Prostate Cancer Metastases
    NIH, PO1
    PI: Paul H. Lange, Eva Corey director of project II, co-investigator on project III
    The goals of this proposal are to investigate roles of osteoprotegerin, RANK ligand in prostate cancer bone metastasis.
  • Evaluation of Roles of Interferon Gamma Regulated Genes in Estradiol Inhibition of Androgen-Independent Prostate Cancer
    Department of Defense, Hypothesis Development Award
    PI: Eva Corey
    The major goals of this project are to evaluate model for studies of estradiol inhibition of prostate cancer and involvement of interferon-regulated genes in this process.
  • Effects of Zoledronic Acid in Combination with RAD001 and AEW541 on CaP
    Pacific Northwest SPORE Pilot Award
    PI: Eva Corey
    The goals of this project are to evaluate effects of combination therapy of zoledronic acid, RAD001 and AEW541 on prostate cancer bone metastases in preclinical setting.
  • Synergy Consortium Targeting New Therapeutics for Lethal Phenotypes for CaP
    Department of Defense, Synergy Consortium
    PI: Jonathan Simons
    Co-investigator: Eva Corey on projects A and B
    This is a multi-institutional proposal to determine which are the important prostate cancer-derived factors that facilitate the growth of prostate cancer in bone, perturb normal bone remodeling, and contribute to the morbidity associated with bone metastasis.
  • Prostate Cancer Metastases: Osteoblastic Response Mechanisms
    VA, Merit Review
    PI: Robert L. Vessella
    The major goals of this project are to evaluate biochemical pathways involved in effects of BMPs on prostate cancer and to characterize phenotypic changes associated with prostate e cancer bone metastasis.
  • Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor(IGF-IR)
    Department of Defense, Idea Development Award, PI: Stephen R. Plymate,
    Co-investigator: Eva Corey
    The major goals of this project are to evaluate effects of administration of anti-IGFR-1 antibody on prostate cancer in preclinical setting.

[to top]

Affiliations

American Association for Cancer Research
Metastasis Research Society
International Bone and Mineral Society
American Association for Bone and Mineral Research
American Association of Advancement of Sciences
European Calcified Tissue Society

Dr Corey is an Ad-hoc reviewer for the Oncogene, Clinical Cancer Research, Journal of Urology, International Journal of Cancer, BMC Cancer, Neoplasia and others.

She serves as a reviewer on prostate cancer and breast cancer research programs of the Department of Defense, and as an Ad-hoc reviewer for Italian Cancer Society, Swiss National Science Foundation, and Scottish Biomedical Research.

[to top]

Selected Publications:

Corey E and Vessella RL. Targeting Factors Involved in Bone Remodeling as Treatment Strategies in Prostate Cancer Bone Metastasis. Clin, Cancer Res. In press 2006.

Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006; 6:15.
[The following link will open a new window. PubMed Abstract]

Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer 2006; 118:222-229.
[The following link will open a new window. PubMed Abstract]

Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis. 2005; 8:253-259.
[The following link will open a new window. PubMed Abstract]

Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005; 65:1710-1718.
[The following link will open a new window. PubMed Abstract]

Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004; 21:381-387.
[The following link will open a new window. PubMed Abstract]

Roudier MP, Corey E, True LD, Higano CS, Ott SM, Vessella RL. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res 2004; 118:311-339.
[The following link will open a new window. PubMed Abstract]

Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004; 91:151-160.
[The following link will open a new window. PubMed Abstract]

Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-beta. Urology 2004; 64:814-820.
[The following link will open a new window. PubMed Abstract]

Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, and Vessella RL. Zoledronic acid exhibits anti-tumor effects on prostate cancer cells in vivo. Clin Cancer Res, 1: 295-306, 2003.
[The following link will open a new window. PubMed Abstract]

Curriculum Vitae [38K PDF*]

*Software capable of displaying a PDF is required for viewing or printing this document. You may download it from the Adobe website at http://www.adobe.com/products/acrobat/readstep2.html

 

[to top]

Portrait of Dr. Eva Corey

Contact Information:

University of Washington Medical Center
Box 356510
1959 N.E. Pacific
Seattle, WA 98195
Ph: (206) 543-1461
FAX: (206) 543-1146